Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/01/04/2804103/0/en/Nexcella-Announces-Dr-Vaishali-Sanchorawala-AL-Amyloidosis-Thought-Leader-Director-of-the-Amyloidosis-Center-at-Boston-University-and-Boston-Medical-Center-Joins-Scientific-Advisor.html
https://www.globenewswire.com//news-release/2023/12/18/2797938/0/en/Nexcella-Announces-Dr-Marko-Radic-Autoimmune-CAR-T-Pioneer-and-Associate-Professor-at-the-University-of-Tennessee-Health-Science-Center-Joins-Scientific-Advisory-Board.html
https://www.globenewswire.com//news-release/2023/12/11/2793986/0/en/Nexcella-Announces-100-Overall-Response-Rate-n-10-23-7-months-Best-Response-Duration-ongoing-for-CAR-T-NXC-201-in-Relapsed-Refractory-AL-Amyloidosis-Patients-at-ASH-2023.html
https://www.globenewswire.com//news-release/2023/11/21/2784161/0/en/Nexcella-Announces-FDA-Approval-of-IND-Application-for-CAR-T-NXC-201-Enabling-U-S-Patient-Dosing.html
https://www.globenewswire.com//news-release/2023/11/06/2774216/0/en/Nexcella-Presents-NXC-201-Data-at-65th-American-Society-of-Hematology-ASH-Annual-Meeting-in-9-Relapsed-Refractory-AL-Amyloidosis-Patients.html
https://www.globenewswire.com//news-release/2023/10/26/2767622/0/en/Nexcella-Announces-Dr-Michaela-Liedtke-Stanford-Medicine-Cancer-Center-Hematology-Program-Lead-and-Co-Director-Stanford-Amyloid-Center-Joins-Scientific-Advisory-Board.html
https://www.globenewswire.com//news-release/2023/10/16/2760748/0/en/Nexcella-Completes-3rd-NXC-201-Engineering-Batch-at-its-U-S-CAR-T-Manufacturing-Site.html
https://www.globenewswire.com//news-release/2023/10/03/2753767/0/en/Nexcella-Announces-Complete-Response-in-9th-Relapsed-Refractory-AL-Amyloidosis-Patient-in-NXC-201-Clinical-Trial-at-IMS-20th-Annual-Meeting.html
https://www.globenewswire.com//news-release/2023/10/02/2752728/0/en/Nexcella-Announces-72-Patient-NXC-201-Clinical-Data-at-the-IMS-20th-Annual-Meeting-95-Overall-Response-Rate-in-Multiple-Myeloma.html
https://www.globenewswire.com//news-release/2023/09/21/2747356/0/en/U-S-Food-and-Drug-Administration-Approves-Orphan-Drug-Designation-for-Nexcella-NXC-201-as-a-Treatment-for-Amyloid-Light-Chain-AL-Amyloidosis.html